K50
Conditions
Interventions
Group 1: Patients with a new diagnosis of active Crohn's disease: documentation of demographic data, history of Crohn's disease, previous extraintestinal manifestations, treatment with Case Report For
Sponsors
AbbVie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with a recent diagnosis (not more than 6 months) of active Crohn's disease = 18 years naïve to conventional immunosuppressives (thiopurines, methotrexate, calcineurin inhibitors, etc) and biologics at baseline
Exclusion criteria
Exclusion criteria: Patients whose diagnosis of active Crohn's disease was made more than 6 months ago Patients who are not naïve to conventional immunosuppressives (thiopurines, methotrexate, calcineurin inhibitors, etc) and biologics at baseline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients (in %) who need immunosuppressive therapy within 24 months from enrollment with at least one of the defined major predictive parameters: - age at onset - ileocolonic disease - joint manifestations - cutaneous manifestations - steroids at first flare - no response to steroids at any flare | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients (in %) who are hospitalized because of their Crohn’s disease within 24 months from enrollment with at least one of the above stated major predictive parameters | — |
Countries
Germany
Contacts
Public ContactAndreas Stallmach
Klinikum der Universität Jena, Klinik für Innere Medizin IV (Gastroenterologie, Hepatologie, Infektiologie)
Outcome results
None listed